HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

BACKGROUND: Targeted therapies have improved therapeutic options of treating renal cell carcinoma (RCC). However, drug response is temporary due to resistance development. METHODS: Functional and molecular changes in RCC Caki-1 cells, after acquired resistance to the mammalian target of rapamycin (m...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Nowaz, Snigdha, Makarevi, Jasmina, Natsheh, Iyad, Werner, Isabella, Nelson, Karen, Reiter, Michael, Tsaur, Igor, Mani, Jens, Harder, Sebastian, Bartsch, Georg, Haferkamp, Axel, Blaheta, Roman A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073177/
https://www.ncbi.nlm.nih.gov/pubmed/24935000
http://dx.doi.org/10.1186/1476-4598-13-152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073177/
https://www.ncbi.nlm.nih.gov/pubmed/24935000
http://dx.doi.org/10.1186/1476-4598-13-152

Ejemplares similares